Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • ABO-102: Phase I/II ongoing

    Abeona Therapeutics Inc. (NASDAQ:ABEO), Dallas, Texas Product: ABO-102 (formerly ABX-A, ABX-101) Business: Endocrine/Metabolic Molecular target: N-sulfoglucosamine sulfohydrolase (SGSH) (HNS) Description: Adeno-…

    Published on 8/22/2016
  • AK0529: Phase II started

    Ark Biosciences Inc., Shanghai, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: AK0529 Business: Infectious Molecular target: RSV F protein Description: Small molecule inhibitor of RSV F protein …

    Published on 8/22/2016
  • Amphora: Phase I started

    Evofem Inc., San Diego, Calif. Product: Amphora Business: Infectious Molecular target: NA Description: Non-hormonal vaginal gel Indication: Prevent bacterial vaginosis Endpoint: Vaginal pH over 7 days; change from …

    Published on 8/22/2016
  • BCX7353: Phase II started

    BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. Product: BCX7353 Business: Inflammation Molecular target: Kallikrein Description: Second-generation kallikrein inhibitor Indication: Prevent attacks in patients …

    Published on 8/22/2016
  • Bryostatin-1: Phase IIb amended

    Neurotrope Inc. (OTCQB:NTRP), Newark, N.J. Product: Bryostatin-1 Business: Neurology Molecular target: Protein kinase C (PKC) epsilon (PKCE) Description: Protein kinase C (PKC) epsilon (PKCE) activator Indication: Treat…

    Published on 8/22/2016
  • Cannabidiol: Phase II started

    Insys Therapeutics Inc. (NASDAQ:INSY), Phoenix, Ariz. Product: Cannabidiol (CBD) oral solution Business: Neurology Molecular target: NA Description: Oral solution of synthetic cannabidiol Indication: Treat cocaine …

    Published on 8/22/2016
  • Clonidine topical gel: Completed Phase IIb enrollment

    Arcion Therapeutics Inc., Baltimore, Md. BioDelivery Sciences International Inc. (NASDAQ:BDSI), Raleigh, N.C. Product: Clonidine topical gel (formerly ARC-4558) Business: Neurology Molecular target: Adrenergic receptor …

    Published on 8/22/2016
  • DNX-2401: Phase II started

    DNAtrix Inc., Houston, Texas Product: DNX-2401 Business: Cancer Molecular target: NA Description: Genetically modified oncolytic adenovirus that uses arginine-glycine-aspartic acid (RGD)-binding integrins to enter and …

    Published on 8/22/2016
  • Durvalumab: Phase I started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Durvalumab (MEDI4736) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting PD-L1 …

    Published on 8/22/2016
  • Guadecitabine: Phase I/II started

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Guadecitabine (SGI-110) (formerly S110) Business: Cancer Molecular target: DNA (cytosine-5-)-methyltransferase 1 (DNMT1) Description: Small molecule DNA …

    Published on 8/22/2016
  • INO-4212: Phase I ongoing

    Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: INO-4212 Business: Infectious Molecular target: NA Description: Ebola virus vaccine combining INO-4201, which contains the DNA sequence that codes for …

    Published on 8/22/2016
  • Liprotamase: Phase III ongoing

    Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase (Sollpura) (LY3031642) Business: Gastrointestinal Molecular target: Not available …

    Published on 8/22/2016
  • Lucassin terlipressin: Phase III started

    Alliance Pharma plc (LSE:APH), Chippenham, U.K. Orphan Therapeutics LLC, Lebanon, N.J. Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Product: Lucassin terlipressin Business: Hepatic Molecular target: Vasopressin 1 (V1) …

    Published on 8/22/2016
  • Mipsagargin: Phase II started

    Inspyr Therapeutics Inc. (OTCQB:NSPX), San Antonio, Texas Product: Mipsagargin (G-202) Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Prodrug of plant-derived …

    Published on 8/22/2016
  • MLE4901: Phase IIb started

    Millendo Therapeutics Inc., Ann Arbor, Mich. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: MLE4901, AZD4901 Business: Genitourinary Molecular target: Neurokinin 3 (NK3) receptor (TACR3) (NK3R) Description: …

    Published on 8/22/2016
  • OBE022: Phase I started

    ObsEva S.A., Geneva, Switzerland Product: OBE022 Business: Genitourinary Molecular target: Prostaglandin F2 alpha receptor (PGF2 alpha) Description: Prostaglandin F2 alpha receptor (PGF2 alpha) antagonist Indication: …

    Published on 8/22/2016
  • Omadacycline: Phase III started

    Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), Boston, Mass. Product: Omadacycline (formerly PTK 0796) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Aminomethylcycline antibiotic Indication: …

    Published on 8/22/2016
  • RP-G28: Completed Phase IIb/III enrollment

    Ritter Pharmaceuticals Inc. (NASDAQ:RTTR), Los Angeles, Calif. Product: RP-G28 Business: Gastrointestinal Molecular target: NA Description: Short chain oligosaccharide used to stimulate colonic growth of lactose-…

    Published on 8/22/2016
  • SAB-301: Phase I started

    SAB Biotherapeutics Inc., Sioux Falls, S.D. Product: SAB-301 Business: Infectious Molecular target: NA Description: Human polyclonal Ig produced from transchromosomic cattle that targets Middle East respiratory syndrome…

    Published on 8/22/2016
  • Tideglusib: Phase II started

    AMO Pharma Ltd., Wonersh, U.K. Noscira S.A., Madrid, Spain Product: Tideglusib (AMO-02) (formerly NP-12) Business: Musculoskeletal Molecular target: Glycogen dependent kinase 3 (GSK3) Description: Glycogen dependent …

    Published on 8/22/2016
  • Tirasemtiv: Completed Phase III enrollment

    Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Product: Tirasemtiv (formerly CK-2017357) Business: Neurology Molecular target: Sarcomere Description: Fast skeletal muscle troponin activator Indication: …

    Published on 8/22/2016
  • Tivicay dolutegravir: Phase III started

    ViiV Healthcare Ltd., Brentford, U.K. Product: Tivicay dolutegravir Business: Infectious Molecular target: HIV integrase Description: HIV integrase inhibitor Indication: Treat HIV-1 infection in treatment-naive patients…

    Published on 8/22/2016
  • Tivozanib: Phase I/II started

    EUSA Pharma Ltd., Hemel Hempstead, U.K. Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Tivozanib (ASP4130, AV-951) (formerly KRN951) Business: …

    Published on 8/22/2016
  • TTP273: Completed Phase II enrollment

    vTv Therapeutics Inc. (NASDAQ:VTVT), High Point, N.C. Product: TTP273 Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Description: Small molecule, non-peptide glucagon-…

    Published on 8/22/2016
  • Vadadustat: Phase III started

    Akebia Therapeutics Inc. (NASDAQ:AKBA), Cambridge, Mass. Product: Vadadustat (formerly AKB-6548) Business: Hematology Molecular target: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) Description: Oral …

    Published on 8/22/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993